综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

National

Regional

Taiwan, HK, Macao

Special Coverage

Focus

Society

Profiles

China starts batch production of A(H1N1) vaccine

(Xinhua/CRIENGLISH.com)
Updated: 2009-06-09 17:28

Sinovac Biotech Company, a vaccine-focused biotech company in China, started efforts to manufacture A(H1N1) influenza vaccine for human use on Monday, after it received the flu strain samples from the WHO, Beijing News reported Tuesday.

A researcher with Sinovac Biotech Company begins preparation work for producing A/H1N1 influenza vaccine for human use with the seed lot of flu virus "NYMCX-179A". [Xinhua]

There are another 10 Chinese drug companies that will obtain the flu strain samples "NYMCX-179A" from the WHO this week. China has a total of 11 drug companies that can produce seasonal flu vaccines, but Sinovac Biotech Company is the only one that can make pandemic flu vaccines.

On Monday, Sinovac Biotech Company announced it will share key techniques and cooperate with other flu vaccine producers in a bid to rapidly expand the vaccine production.

Also on the same day, the State Food and Drug Administration held a press conference, announcing it will organize and coordinate 11 drug companies in manufacturing vaccines in case of a pandemic of A(H1N1) influenza.

Special coverage: A(H1N1) Influenza Outbreak Related readings:  GSK sees opportunity in China  China may have vaccine to new flu by July  HK gov't to procure new flu vaccine for public  WHO: H1N1 flu vaccine delayed until mid-July  Drug firms play waiting game for vaccine

Head of the biology production department under the State Food and Drug Administration, Yin Hongzhang, ensured the vaccines, which could be directly injected into the high-risk population, would be yielded by October 1. But he added that the experiments on the vaccine's safety and effectiveness are necessary before batch production.

Yin Hongzhang also predicted in case of a global epidemic, China's annual vaccine production capacity is expected to reach 360 million if all the eleven domestic drug companies are approved for the batch production of A(H1N1) vaccines.

Earlier, the drug administration noted that the WHO was not sure yet whether the A(H1N1) flu should be categorized as seasonal or pandemic, which was a problem for drug makers.

   Previous page 1 2 3 Next Page  

   Previous page 1 2 3 Next Page